Mavacamten ready for “compassionate use”, perhaps in a year it will be refundable

Mavacamten and Aficamten are the two new drugs for the treatment of hypertrophic cardiomyopathy. Mavacamten has entered the “compassionate” use phase. This means that the drug is already available and can be supplied by the manufacturer for patients with hypertrophic obstructive cardiomyopathy, upon request by expert cardiologists. Aficamten is a little further behind in the experimentation process.

February 21 2024|

Volunteers doubled in Careggi, supporting patients after the "tsunami" of the diagnosis

Aicarm operates in the context of a region that is very rich in terms of volunteering, which is an enormous social capital. At the cardiomyopathy diagnosis and treatment unit in Careggi, the number of volunteers who make themselves available to patients facing their first diagnosis or going there for a check-up is increasing. They inform them and make themselves available to them for every need. It is a service of the same nature as Hearts in Listening, but with direct human contact. 

February 20 2024|

Cardiac arrest: how to improve complication-free survival after cardiopulmonary resuscitation (CPR)

Reflections on a study appearing in the Journal of the American College of Cardiology which reports the evolution of the incidence, management and prognosis of AC in athletes in France. The complication-free survival rate tripled. In Italy it is necessary to extend CPR training programs and increase the installation of AEDs, also involving middle and high school students and installing AEDs in all workplaces as well as in sports.

January 29 2024|

Success of the Cuori in Ascolto service: the answers to patients that the web and social networks cannot give

To help people diagnosed with cardiomyopathy, AICARM has activated a listening desk managed by volunteers and experts: Cuori in Ascolto. AICARM has trained a group of volunteers who, in addition to being carriers of a cardiomyopathy themselves, have acquired basic knowledge on the diagnosis, the different therapies and the pathogenesis of cardiomyopathies. I am able to actively listen to the patient or a family member and establish an empathetic relationship, creating contact between two people who share similar problems. 

December 16 2023|

Green light for Mavacamten: the compassionate use phase begins

Mavacamten is the first approved drug of a new class of drugs, which reduce the activity of "cardiac myosin", a protein fundamental for the contraction of heart cells, which plays a decisive role in creating obstruction to the outflow of blood left ventricle in most patients with hypertrophic obstructive cardiomyopathy. A few weeks ago, the activation of the Compassionate Use Program was officially published on the AIFA website.

December 16 2023|

AICARM courses: great demand, soon also online training activities

2024 will see AICARM still committed to disseminating knowledge on cardiomyopathies, we will organize other courses for expert patients during the year. However, we have seen that there is a growing demand for knowledge about cardiomyopathies. And providing answers with in-person courses is not enough to cover patients' requests and, for this reason, next year AICARM will combine the in-person courses with other training activities carried out online. 

December 13 2023|

Shortage of the drug Nadolol: AICARM requests the intervention of AIFA

The shortage of Nadolol in pharmacies is increasingly worrying doctors and patients and for this reason AICARM APS has decided to contact the director of the Italian Medicines Agency Domenico Di Giorgio to request urgent intervention. In a letter sent on 4 December 2023, President Franco Cecchi, together with the pharmacologist Alessandro Mugelli, asked AIFA to take action to ensure the availability of Nadolol in pharmacies (including by importing it from abroad) and to request its production from the Institute Military Pharmaceutical of Florence.

December 13 2023|
Back to the top